Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 17/20 | 0.80 |
| ▸ | HTR1A | P08908 | 15/20 | 0.80 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.80 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14862180 | 0.98 | SLC6A2 (0.77) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| Trifluoroacetic Acid SCHEMBL21590502 | 0.86 | SLC6A2 (0.61) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL24136423 | 0.85 | SLC6A2 (0.61) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL17633300 | 0.85 | SLC6A2 (0.61) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL5107334 | 0.85 | SLC6A2 (0.82) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL23830677 | 0.85 | SLC6A2 (0.82) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL17633298 | 0.85 | SLC6A2 (0.61) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL23830680 | 0.85 | SLC6A2 (0.82) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL17643338 | 0.85 | SLC6A2 (0.61) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL20176345 | 0.85 | SLC6A2 (1.00) | SLC6A2HTR1ASLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2861605-B1 | 6-Benzyl-6H-thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one derivatives as phosphodiesterase-1 (PDE-1) inhibitors for the treatment of e.g. neurological, cognitive and cardiovascular disorders | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2017-05-03 | — | — | EP | claimed |
| US-9499562-B2 | Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2016-11-22 | — | — | US | claimed |
| US-20160031901-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | DART NEUROSCIENCE LLC | 2016-02-04 | — | — | US | claimed |
| CN-104583217-A | Substituted thiophene-fused and furan-fused oxazolopyrimidine-5- (6H) -one compounds | DART NEUROSCIENCE CAYMAN LTD | 2015-04-29 | — | — | CN | claimed |
| EP-2861605-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | Dart Neuroscience (Cayman) Ltd (KY) | 2015-04-22 | — | — | EP | claimed |
| WO-2013192225-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2013-12-27 | — | — | WO | claimed |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-08-24 | — | — | US | disclosed |
| US-20210292305-A1 | Cyclic Ureas | SIRONAX LTD (KY) | 2021-09-23 | — | — | US | disclosed |
| US-20210292305-A1 | Cyclic Ureas | SIRONAX LTD (KY) | 2021-09-23 | — | — | US | disclosed |
| CN-113302183-A | Cyclic ureas | 圣瑞诺有限公司 | 2021-08-24 | — | — | CN | disclosed |
| US-10092575-B2 | Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-10-09 | — | — | US | disclosed |
| US-20170209459-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | DART NEUROSCIENCE LLC | 2017-07-27 | — | — | US | disclosed |
| EP-2861605-B1 | 6-Benzyl-6H-thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one derivatives as phosphodiesterase-1 (PDE-1) inhibitors for the treatment of e.g. neurological, cognitive and cardiovascular disorders | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2017-05-03 | — | — | EP | disclosed |
| CN-104583217-A | Substituted thiophene-fused and furan-fused oxazolopyrimidine-5- (6H) -one compounds | DART NEUROSCIENCE CAYMAN LTD | 2015-04-29 | — | — | CN | disclosed |
| EP-2861605-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | Dart Neuroscience (Cayman) Ltd (KY) | 2015-04-22 | — | — | EP | disclosed |
| WO-2013192225-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2013-12-27 | — | — | WO | disclosed |
| CN-101583600-A | Acetylene derivatives as stearoyl-CoA desaturase inhibitors | GLENMARK PHARMACEUTICALS SA (CH) | 2009-11-18 | — | — | CN | disclosed |
| EP-2099755-A2 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2009-09-16 | — | — | EP | disclosed |
| US-20080182851-A1 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-07-31 | — | — | US | disclosed |
| WO-2008062276-A2 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10092575-B2 | Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds | TPMT, PSEN2, GRIN2C | SLC6A2 612/4885HTR1A 202/4885SLC6A3 495/4885 |
| US-20080182851-A1 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | SCD, SCD5, ACACA | SLC6A2 4488/4885HTR1A 3789/4885SLC6A3 4681/4885 |
| US-20160031901-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | TPMT, PSEN2, GRIN2C | SLC6A2 565/4885HTR1A 179/4885SLC6A3 474/4885 |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | SLC6A2 4715/4885HTR1A 4632/4885SLC6A3 4458/4885 |
| US-20210292305-A1 | Cyclic Ureas | RIPK1, RIPK3, RIPK4 | SLC6A2 4844/4885HTR1A 2665/4885SLC6A3 4703/4885 |
| US-20170209459-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | TPMT, PSEN2, GRIN2C | SLC6A2 612/4885HTR1A 202/4885SLC6A3 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.